Articles

Podcasts

Videos

Clinical

Advances in the Treatment Landscape for HIV

Relying solely on blood tests means clinicians may miss cases of potentially deadly M tuberculosis&mdash;and waiting days to treat suspected cases could prove fatal.

Mycobacterium tuberculosis in Patients With HIV Carries Mortality Risk

Ian Frank, MD, discusses upcoming treatments for people with HIV.

Long-Acting ART, Islatravir, and Capsid Inhibitors

Patients facing HIV stigma may encounter difficulties with retention in care.

People Facing HIV Stigma Are Less Likely To Make Their Next Care Visit

George Hanna, MD, vice president and therapeutic head of infectious diseases at Merck Laboratories, discusses data from CROI 2020 on islatravir.

George Hanna, MD: Islatravir Presentations at CROI 2020

The US government has ambitious goals to expand the number of people tested and treated for HIV in the coming years. A new study details the best interventions to make the biggest difference for the most people.

A Modeling Study Points the Way to Stopping HIV Spread

Ian Frank, MD, explains the "Ending the Epidemic" initiative.

What "Ending the HIV Epidemic" Entails

Colleen Kelley, MD, MPH, describes the current state of HIV vaccine efforts.

The HIV Vaccine Landscape

An antibody gene delivered by a harmless virus produced anti-HIV antibodies for a sustained period.

Virus-Delivered Anti-HIV Antibody Shows Promise in NIH Study

HIV pre-exposure prophylaxis appears to be making a difference, according to new research, which showed an association between increases in PrEP coverage and decreases in HIV diagnosis rates in the United States.

SEXUALLY TRANSMITTED DISEASES